Anti-EpCAM antibodies for detection of metastatic carcinoma in effusions and peritoneal wash

Epithelial cell adhesion molecule (EpCAM) has been used as diagnostic/prognostic marker and therapeutic target. The aim of the present study was to compare immunoreactivity of antibodies against distinct epitopes in the ectodomain of EpCAM for detection of carcinoma from different primary sites and...

Full description

Saved in:

Bibliographic Details
Published in:	Oncology letters Vol. 18; no. 2; pp. 2019 - 2024
Main Authors:	Carneiro, Fabiana Pirani, Muniz-Junqueira, Maria Imaculada, De Vasconcelos Carneiro, Marcos, De Araújo Oliveira, Ísis, Soares, Aluízio Carlos, De Vargas Haar, Nathália, Takano, Gustavo Henrique Soares, De Sousa Vianna, Leonora Maciel, De Carvalho Caldas, Guilherme, Vieira, Danillo Leal Marinho, Frutuoso, Lígia Lins, Brito, Larissa Matos Rodrigues, De Siqueira, Rafael Vieira Martins, Parente, Amanda Moreira, De Castro, Tercia Maria Mendes Lousa, Peres, Isabela, Mendes, Lianna Martha Soares, Dos Santos Borges, Tatiana Karla, Ferreira, Vânia Moraes, Motoyama, Andrea Barretto
Format:	Journal Article
Language:	English
Published:	Greece Spandidos Publications 01-08-2019 Spandidos Publications UK Ltd D.A. Spandidos
Subjects:	Adenocarcinoma Antibodies Antigenic determinants Antigens Cancer Cancer metastasis Carcinoma Cell adhesion & migration Cysteine Cystine Epidermal growth factor Epidermal growth factors Gastric cancer Health aspects Immunoglobulins Medical prognosis Metastasis Oncology Squamous cell carcinoma Tumors Brazil cytology immunocytochemistry cancer carcinoma effusions epithelial cell adhesion molecule
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Epithelial cell adhesion molecule (EpCAM) has been used as diagnostic/prognostic marker and therapeutic target. The aim of the present study was to compare immunoreactivity of antibodies against distinct epitopes in the ectodomain of EpCAM for detection of carcinoma from different primary sites and of different histological types in effusions and peritoneal wash. Two antibodies against epitopes in the EGF-like domain I (clones Moc-31 and Ber-EP4) and one antibody against the epitope in the cysteine-poor region (158210) of EpCAM were used (all commercially available). Independently of the clone used, EpCAM overexpression was observed in almost all samples when all the adenocarcinoma samples were analyzed together. By using Moc-31, EpCAM overexpression was observed in all samples of adenocarcinoma. Absence of EpCAM overexpression was observed in a few adenocarcinoma samples at some sites of tumor origin, including ovary, breast and stomach, when Ber-EP4 and 158210 were used. Regarding carcinomas aside from adenocarcinomas, histological types, such as squamous cell, urothelial and small cell carcinoma showed different degrees of EpCAM expression according to the antibody used. In squamous cell carcinoma, overexpression was observed only with the clone 158210. It was concluded that, overall, most samples of metastatic carcinoma from effusions showed overexpression of EpCAM. However, there are significant variations in its detection according to the primary site, histological type of the carcinoma and depending on the antibody used. Thus, the use of more than one type of anti-EpCAM antibody would increase the chance of its detection in metastatic carcinoma effusion.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1792-1074 1792-1082
DOI:	10.3892/ol.2019.10468